Ivonescimab shows four-month survival edge in Harmoni-6 lung cancer trial
Ivonescimab, a PD-1/VEGF bispecific, plus chemotherapy, extended median overall survival by about four months in squamous NSCLC in the Harmoni-6 Phase 3 trial conducted in China; results need confirmation in broader populations and safety signals (bleeding) were noted, with global Harmoni-3 results expected later.